VIDEO: PROpel, MAGNITUDE studies provide promise for PARP inhibitors for prostate cancer
In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses recent developments related to PARP inhibitors and their effect on prostate cancer presented at ASCO Annual Meeting.
Dorff first examines the PROpel and MAGNITUDE studies, which showed positive results and raised the possibility that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib could have broader application in unselected molecular populations.
Dorff also touches on the BREAKAWAY study presented by Maha Hussain, MD, which looks to clear up confusion on how to use abiraterone.
- Saad F, et al. PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
- Chi K, et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.